Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
P/B ratio for Siegfried Holding AG (SFZN.SW)
P/B ratio as of 2023: 4.35
According to Siegfried Holding AG's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.35. At the end of 2022 the company had a P/B ratio of 3.64.
P/B ratio history for Siegfried Holding AG from 2002 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.35 |
| 2022 | 3.64 |
| 2021 | 6.15 |
| 2020 | 5.45 |
| 2019 | 4.45 |
| 2018 | 2.02 |
| 2017 | 1.93 |
| 2016 | 1.25 |
| 2015 | 1.57 |
| 2014 | 1.64 |
| 2013 | 1.75 |
| 2012 | 1.30 |
| 2011 | 0.89 |
| 2010 | 0.82 |
| 2009 | 0.79 |
| 2008 | 0.72 |
| 2007 | 1.11 |
| 2006 | 1.13 |
| 2005 | 1.05 |
| 2004 | 0.99 |
| 2003 | 1.07 |
| 2002 | 1.14 |